<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2232">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586975</url>
  </required_header>
  <id_info>
    <org_study_id>Aspirin Resistance and Stroke</org_study_id>
    <secondary_id>IRB#0996-007 FUND#7810</secondary_id>
    <nct_id>NCT01586975</nct_id>
  </id_info>
  <brief_title>Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events</brief_title>
  <official_title>Multiphase Study to Determine if Platelet Function Analysis Results Correlate With Ischemic Events and Bleeding Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if PFA results correlate with ischemic event
      outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more
      efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherothrombotic disease is a leading killer of adults throughout the world. The current
      mainstay for the prevention of ischemic vascular events is the use of aspirin Antiplatelet
      agents are used routinely for the primary and secondary prevention of vascular events in
      patients with a prior history of stroke, TIA, or at high risk for the development of
      cerebrovascular disease. Numberous individual studies and meta-analyses have shown that
      essentially all of the oral antiplatelet agents have limited efficacy, with relative risk
      reductions in the range of 20-35%. The purpose of this study is to perform serial platelet
      function assays (PFAs) on patients with cerebrovascular disease who are taking antiplatelet
      agents and perform a pilot study to determine the feasibility of administering ASA as a dose
      adjusted medication using PFA. The long term goal of this study is to determine whether
      antiplatelet therapy will be more efficacious and/or safer if it is administered in a
      dose-adjusted manner.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PFA1</measure>
    <time_frame>3-6 months (Collected once between regulalary scheduled follow-up visit between 3-6 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Platelet Function Analysis (PFA) lab results: PFA was performed using the PFA 100 device (Dade-Behring), which uses a higher sheer stress flow cytometry paradigm to measure the time in seconds to closing of an aperture. Normal is defined as &lt;172 seconds.&quot;</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Stroke</condition>
  <condition>Myocardial Infarctions</condition>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 81 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open-label Aspirin 81 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin &gt; 300mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open-label Aspirin over 300 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75 mg QD</description>
    <arm_group_label>Clopidogrel 75 mg</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81 mg</intervention_name>
    <description>Aspirin 81mg QD</description>
    <arm_group_label>Aspirin 81 mg</arm_group_label>
    <other_name>Acetylsalicylic Acid</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin &gt;300 mg</intervention_name>
    <description>Aspirin &gt;300 mg QD</description>
    <arm_group_label>Aspirin &gt; 300mg</arm_group_label>
    <other_name>Acetylsalicylic Acid</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be taking Aspirin or Plavix

          -  Patient must have had a stroke, TIA or cerebrovascular disease

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Alberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996 Sep;27(9):1459-66. Review.</citation>
    <PMID>8784113</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 2, 2015</lastchanged_date>
  <firstreceived_date>August 3, 2011</firstreceived_date>
  <firstreceived_results_date>June 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with cerebrovascular disease and taking one or more antiplatelet medication were consented for study participation from 2007 though 2010. Patients were recruiting on the inpatient stroke unit at Northwestern Memorial Hospital and seen in the outpatient stroke clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Clopidogrel 75 mg</title>
          <description>Clopidogrel 75 mg QD</description>
        </group>
        <group group_id="P2">
          <title>Aspirin 81 mg</title>
          <description>Aspirin 81 mg QD</description>
        </group>
        <group group_id="P3">
          <title>Aspirin &gt; 300 mg</title>
          <description>Aspiring &gt; 300 mg QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clopidogrel 75 mg</title>
          <description>Clopidogrel 75 mg QD</description>
        </group>
        <group group_id="B2">
          <title>Aspirin 81 mg</title>
          <description>Aspirin 81 mg QD</description>
        </group>
        <group group_id="B3">
          <title>Aspiring &gt;300 mg</title>
          <description>Aspirin &gt;300 mg QD</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="46"/>
                <measurement group_id="B4" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.6" lower_limit="37" upper_limit="83"/>
                <measurement group_id="B2" value="67.4" lower_limit="36" upper_limit="93"/>
                <measurement group_id="B3" value="56.2" lower_limit="21" upper_limit="87"/>
                <measurement group_id="B4" value="60.7" lower_limit="21" upper_limit="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="26"/>
                <measurement group_id="B4" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="7"/>
                <measurement group_id="B4" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="37"/>
                <measurement group_id="B4" value="75"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="46"/>
                <measurement group_id="B4" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PFA1</title>
        <description>Platelet Function Analysis (PFA) lab results: PFA was performed using the PFA 100 device (Dade-Behring), which uses a higher sheer stress flow cytometry paradigm to measure the time in seconds to closing of an aperture. Normal is defined as &lt;172 seconds.&quot;</description>
        <time_frame>3-6 months (Collected once between regulalary scheduled follow-up visit between 3-6 months)</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Clopidogrel 75 mg</title>
            <description>Clopidogrel 75 mg QD</description>
          </group>
          <group group_id="O2">
            <title>Aspirin 81 mg</title>
            <description>open label Aspirin</description>
          </group>
          <group group_id="O3">
            <title>Aspirin &gt; 300 mg</title>
            <description>open-label Aspirin</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>PFA1</title>
            <description>Platelet Function Analysis (PFA) lab results: PFA was performed using the PFA 100 device (Dade-Behring), which uses a higher sheer stress flow cytometry paradigm to measure the time in seconds to closing of an aperture. Normal is defined as &lt;172 seconds.&quot;</description>
            <units>seconds</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="202.0" spread="27.1"/>
                  <measurement group_id="O2" value="271.1" spread="14.9"/>
                  <measurement group_id="O3" value="234.7" spread="13.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis non-parametric ANOVA test</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0742</p_value>
            <p_value_desc>p-value is not adjusted, and no a priori threshold was used</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were monitored via routine clinic/office visits to determine if they had an ischemic vascular event or hemorrhagic event. These follow-up visits were scheduled every 3-6 months as per their regularly scheduled clinic follow-up visits.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clopidogrel 75 mg</title>
          <description>Clopidogrel 75 mg QD</description>
        </group>
        <group group_id="E2">
          <title>Aspirin 81 mg</title>
          <description>Aspirin 81 mg QD</description>
        </group>
        <group group_id="E3">
          <title>Aspirin &gt;300 mg</title>
          <description>Aspirin &gt;300 mg QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MI</sub_title>
                <description>one patient suffered a MI</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Clinical Stroke</sub_title>
                <description>one patient suffered a clinical stroke</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>TIA</sub_title>
                <description>one patient suffered from a TIA</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleeding</sub_title>
                <description>minor GI bleeding/blood in stool</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>minor bruising</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Nose bleeds</sub_title>
                <description>4 patients suffered from nose bleeds</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Northwestern University</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312.503.4394</phone>
      <email>r-bernstein@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
